Your Health, We Care
Upadacitinib is a reversible and orally selective JAK1 inhibitor developed and produced by AbbVie in the United States. It has shown significant efficacy and broad application prospects in the treatment of various immune-mediated diseases.
Upadacitinib has been approved for the treatment of various immune-mediated diseases, including rheumatoid arthritis (RA), atopic dermatitis (AD), psoriatic arthritis (PsA), etc. With the continuous development of biotechnology and the emergence of innovative drugs, Upadacitinib is expected to become one of the important drugs for treating immune-mediated diseases in the future.
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
